{"id":910676,"date":"2025-11-17T08:36:14","date_gmt":"2025-11-17T13:36:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/"},"modified":"2025-11-17T08:36:14","modified_gmt":"2025-11-17T13:36:14","slug":"protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/","title":{"rendered":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology"},"content":{"rendered":"
\n

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Na\u00efve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2025 to December 5, 2025, in Phoenix, Arizona. The presentation will include data featured in the abstract published on the\u00a0SUO website<\/a>, as well as updated safety and efficacy data from 31 enrolled BCG-Na\u00efve patients, the majority of whom have reached the six-month evaluation time point.<\/p>\n

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (\u00b1 Ta\/T1) who are Bacillus Calmette-Gu\u00e9rin (BCG)-Unresponsive (n\u2248100) or BCG-Na\u00efve (n=31). Trial subjects received an induction course, with or without a reinduction, of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months.<\/p>\n

\n Details of the poster presentation are as follows:<\/strong>\n <\/p>\n

\n Title:<\/strong> ADVANCED-2: Preliminary Efficacy and Safety Data in BCG-Na\u00efve Participants with High-Grade Non-Muscle Invasive Bladder Cancer
Poster Number:<\/strong> 149
Poster Category:<\/strong> NMIBC
Session Title:<\/strong> Bladder Cancer
Session Date and Time:<\/strong> Thursday, December 4, 2025, 2:30 p.m. \u2013 3:30 p.m. CT<\/p>\n

\n About TARA-002<\/strong>\n <\/p>\n

TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the\u00a0U.S. Food and Drug Administration. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil\u00ae in\u00a0Japan\u00a0by Chugai Pharmaceutical Co., Ltd. Protara has successfully shown manufacturing comparability between TARA-002 and OK-432.<\/p>\n

When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with release of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma IL-6, IL-10, IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.<\/p>\n

\n About Non-Muscle Invasive Bladder Cancer (NMIBC)<\/strong>\n <\/p>\n

Bladder cancer is the sixth most common cancer in\u00a0the\u00a0United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in\u00a0the United States\u00a0each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle.<\/p>\n

\n About\u00a0Protara Therapeutics, Inc.<\/strong>\n <\/p>\n

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na\u00efve to treatment with Bacillus Calmette-Gu\u00e9rin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit\u00a0www.protaratx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Statements contained in this press release regarding matters that are not historical facts are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cdesigned,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara\u2019s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara\u2019s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including the timing of any particular phases of such trials and the timing of the announcement of any data produced during such trials or phases thereof); statements related to expectations regarding interactions with the\u00a0U.S. Food and Drug Administration\u00a0(FDA); Protara\u2019s financial position; statements regarding the anticipated safety or efficacy of Protara\u2019s product candidates; and Protara\u2019s outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara\u2019s financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara\u2019s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara\u2019s strategic and commercial plans; Protara\u2019s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general\u00a0U.S.\u00a0and foreign, economic, industry, market, regulatory, political or public health conditions; and the risks and uncertainties associated with Protara\u2019s business and financial condition in general, including the risks and uncertainties described more fully under the caption \u201cRisk Factors\u201d and elsewhere in Protara’s filings and reports with the\u00a0United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.<\/p>\n

\n Company Contact:<\/strong>\n <\/p>\n

Justine O’Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Na\u00efve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2025 to December 5, 2025, in Phoenix, Arizona. The presentation will include data featured in the abstract published on the\u00a0SUO website, as well as updated safety and efficacy data from 31 enrolled BCG-Na\u00efve patients, the majority of whom have reached the … <\/p>\n

Continue reading “Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910676","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nProtara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Na\u00efve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2025 to December 5, 2025, in Phoenix, Arizona. The presentation will include data featured in the abstract published on the\u00a0SUO website, as well as updated safety and efficacy data from 31 enrolled BCG-Na\u00efve patients, the majority of whom have reached the … Continue reading "Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T13:36:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology\",\"datePublished\":\"2025-11-17T13:36:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/\"},\"wordCount\":1062,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/\",\"name\":\"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=\",\"datePublished\":\"2025-11-17T13:36:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Market Newsdesk","og_description":"NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Na\u00efve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2025 to December 5, 2025, in Phoenix, Arizona. The presentation will include data featured in the abstract published on the\u00a0SUO website, as well as updated safety and efficacy data from 31 enrolled BCG-Na\u00efve patients, the majority of whom have reached the … Continue reading \"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-17T13:36:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology","datePublished":"2025-11-17T13:36:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/"},"wordCount":1062,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/","name":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=","datePublished":"2025-11-17T13:36:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjcyNyM3MjY2OTM5IzIxODk3Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-new-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-bcg-naive-nmibc-patients-at-the-26th-annual-meeting-of-the-society-of-urologic-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Na\u00efve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910676"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910676\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}